Tests IBI363 in adults with advanced solid cancers
Tests the drug IBI363 in adults with advanced melanoma, lung, colorectal or kidney cancer.
Key facts
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Where
- Dearborn, Fairway, Houston, Ocala, Plantation, San Francisco, Seattle, and Troy, United StatesSee the 9 sites
- Trial code
- Registry title
- A Study of IBI363 in Subjects with Advanced Solid Malignancies
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 178 people, planned
- Started
- 8 Apr 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- IBI363
- Record updated
- 19 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumours that have not responded to earlier treatment (melanoma, non-small cell lung, colorectal or kidney cancer). It tests the study drug IBI363.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Advanced solid tumours (melanoma, non-small cell lung cancer, colorectal cancer, renal cell cancer); the summary calls them refractory.
- Earlier treatment
- Waiting time needed before the first dose: chemotherapy or targeted small molecule therapy, 2 weeks or 5 plasma half-lives; nitrosoureas and mitomycin C, 6 weeks; any anti-cancer monoclonal antibody, 4 weeks; live vaccines, 28 days.
Main reasons for not taking part
- Poor bone marrow and organ function
- Side effects from earlier cancer treatment not yet down to Grade 0 or 1
- Major surgery within 4 weeks before the first dose, or planned during the study
- Severe unhealed wounds, trauma or ulcers
- Live vaccine within 28 days before the first dose, or planned during the study
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Subjects have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol
- Male or female subjects ≥ 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Anticipated life expectancy of ≥ 3 months
Who cannot take part
- Received previous anti-tumor therapy: Any chemotherapy or targeted small molecule therapy (standard or investigational) within 2 weeks or 5 plasma half-lives. Received Nitrosoureas and mitomycin C within 6 weeks prior to first dose of study drug and during study; Any anti-cancer monoclonal antibody (mAb) within 4 weeks prior to first dose
- Received live vaccines within 28 days prior to first administration of the study drug or plan on receiving any live vaccine during the study
- Has adverse reactions resulting from previous antitumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI-CTCAE v5.0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to investigator' discretion) or baseline prior to the first dose of the study drug
- Undergone major surgery (Craniotomy, thoracotomy or laparotomy, and other surgery according to investigator' discretion, excluding needle biopsy) within 4 weeks prior to the first dose of the study drug, or who are expected to undergo major surgery during the study period, or who have severe unhealed wounds, trauma, ulcers, etc
- Inadequate bone marrow and organ function
Where in United States
- Michigan Hematology & Oncology Consultants - MedOnc DearbornDearborn, United StatesContact: Faisal Musa, MDTaking people
- University of Kansas Medical Center (KUMC)Fairway, United StatesContact: Saqib Abbasi, MDTaking people
- MD Anderson Cancer Center - University of TexasHouston, United StatesContact: Sarina Piha-Paul, MDTaking people
- Oncology Consultants, P.A.Houston, United StatesContact: Mahran ShoukierTaking people
- Ocala Oncology CenterOcala, United StatesContact: Ketan Doshi, MDTaking people
- BRCR Medical CenterPlantation, United StatesContact: Chintan Gandhi, MDTaking people
- University of California, San Francisco (UCSF)San Francisco, United StatesContact: Katy Tsai, MDTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Diane Tseng, MDTaking people
- Michigan Hematology & Oncology Consultants - MedOnc TroyTroy, United StatesContact: Laura Nadeau, MDTaking people
About the trial
What the trial wants to find out
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
The group in the trial
- IBI363Treatment being tested
IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
- Plain-language title
- Tests IBI363 in adults with advanced solid cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 December 2024